JP2021535900A5 - - Google Patents

Info

Publication number
JP2021535900A5
JP2021535900A5 JP2021500808A JP2021500808A JP2021535900A5 JP 2021535900 A5 JP2021535900 A5 JP 2021535900A5 JP 2021500808 A JP2021500808 A JP 2021500808A JP 2021500808 A JP2021500808 A JP 2021500808A JP 2021535900 A5 JP2021535900 A5 JP 2021535900A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
antibody
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500808A
Other languages
English (en)
Japanese (ja)
Other versions
JP7476165B2 (ja
JP2021535900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070430 external-priority patent/WO2020025576A1/en
Publication of JP2021535900A publication Critical patent/JP2021535900A/ja
Publication of JP2021535900A5 publication Critical patent/JP2021535900A5/ja
Priority to JP2024067072A priority Critical patent/JP2024099639A/ja
Application granted granted Critical
Publication of JP7476165B2 publication Critical patent/JP7476165B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500808A 2018-07-31 2019-07-30 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Active JP7476165B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067072A JP2024099639A (ja) 2018-07-31 2024-04-17 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862712691P 2018-07-31 2018-07-31
DE102018118550.2 2018-07-31
US62/712,691 2018-07-31
DE102018118550 2018-07-31
US201862717462P 2018-08-10 2018-08-10
DE102018119555.9 2018-08-10
DE102018119555 2018-08-10
US62/717,462 2018-08-10
PCT/EP2019/070430 WO2020025576A1 (en) 2018-07-31 2019-07-30 Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067072A Division JP2024099639A (ja) 2018-07-31 2024-04-17 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Publications (3)

Publication Number Publication Date
JP2021535900A JP2021535900A (ja) 2021-12-23
JP2021535900A5 true JP2021535900A5 (https=) 2022-08-08
JP7476165B2 JP7476165B2 (ja) 2024-04-30

Family

ID=67514624

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500808A Active JP7476165B2 (ja) 2018-07-31 2019-07-30 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP2024067072A Pending JP2024099639A (ja) 2018-07-31 2024-04-17 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067072A Pending JP2024099639A (ja) 2018-07-31 2024-04-17 がんに対するｂ＊０７拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Country Status (19)

Country Link
US (11) US20200040057A1 (https=)
EP (1) EP3829720A1 (https=)
JP (2) JP7476165B2 (https=)
KR (1) KR20210039334A (https=)
CN (1) CN112512639A (https=)
AU (1) AU2019316160A1 (https=)
BR (1) BR112020027021A2 (https=)
CA (1) CA3106419A1 (https=)
CL (2) CL2021000225A1 (https=)
CO (1) CO2021000534A2 (https=)
CR (1) CR20210054A (https=)
IL (1) IL280544A (https=)
MA (1) MA53326A (https=)
MX (1) MX2021001147A (https=)
PE (1) PE20210316A1 (https=)
PH (1) PH12021550205A1 (https=)
SG (1) SG11202012716TA (https=)
TW (1) TW202019955A (https=)
WO (1) WO2020025576A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992416A1 (ru) * 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
WO2018189148A1 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
EP4103584A4 (en) * 2020-02-12 2024-08-07 La Jolla Institute for Immunology NOVEL CORONAVIRUS T-CELL EPITOPES AND RELATED USES
CA3173666A1 (en) * 2020-04-14 2021-10-21 Claude Perreault Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
JP2024501482A (ja) * 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
EP1280923A2 (en) 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20080113344A1 (en) * 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
WO2014151456A2 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Treatment of inflammatory diseases
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CA3083532C (en) * 2017-12-13 2023-09-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting prame and uses thereof
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法

Similar Documents

Publication Publication Date Title
JP2021535900A5 (https=)
JP2024099580A5 (https=)
JP2024041841A5 (https=)
JP2019511214A5 (https=)
JP2019502360A5 (https=)
JP2021168652A5 (https=)
JP2021514178A5 (https=)
JP2018510628A5 (https=)
JP2018529320A5 (https=)
EP2951202B1 (en) High avidity binding molecules recognizing mage-a1
JP2020516681A5 (https=)
JP2019506838A5 (https=)
JP2019510465A5 (https=)
JP2020191862A5 (https=)
JP2020198875A5 (https=)
JP2022502015A5 (https=)
JP2017502076A5 (https=)
JP2021528046A5 (https=)
JP2018518937A5 (https=)
JP2021101700A5 (https=)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018519243A5 (https=)
JP2018536383A5 (https=)
JP2018509135A5 (https=)
JP2018520653A5 (https=)